MX2023014793A - Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos. - Google Patents
Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos.Info
- Publication number
- MX2023014793A MX2023014793A MX2023014793A MX2023014793A MX2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A MX 2023014793 A MX2023014793 A MX 2023014793A
- Authority
- MX
- Mexico
- Prior art keywords
- klk2
- fusion protein
- nucleic acid
- recombinant cells
- acid coding
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 101710176220 Kallikrein-2 Proteins 0.000 abstract 5
- 102000057032 Tissue Kallikreins Human genes 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21035—Tissue kallikrein (3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
- C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209019P | 2021-06-10 | 2021-06-10 | |
| PCT/IB2022/055355 WO2022259190A1 (en) | 2021-06-10 | 2022-06-08 | Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014793A true MX2023014793A (es) | 2024-03-25 |
Family
ID=82358484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014793A MX2023014793A (es) | 2021-06-10 | 2022-06-08 | Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220403397A1 (enExample) |
| EP (1) | EP4352217A1 (enExample) |
| JP (1) | JP2024520790A (enExample) |
| KR (1) | KR20240021211A (enExample) |
| CN (1) | CN117480253A (enExample) |
| AU (1) | AU2022291273A1 (enExample) |
| BR (1) | BR112023025616A2 (enExample) |
| CA (1) | CA3222756A1 (enExample) |
| IL (1) | IL309179A (enExample) |
| MX (1) | MX2023014793A (enExample) |
| WO (1) | WO2022259190A1 (enExample) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6113917A (en) * | 1995-04-25 | 2000-09-05 | Rmf Dictagene S.A. | Modified polypeptides for enhanced immunogenicity |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| DK1716233T3 (da) * | 2004-01-30 | 2009-10-26 | Maxygen Holdings Ltd | Reguleret stopkodongennemlæsning |
| AU2005295421A1 (en) * | 2004-10-18 | 2006-04-27 | Zymogenetics, Inc. | Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation |
| EP2315846A4 (en) * | 2008-08-05 | 2011-11-30 | Univ Rochester | PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES |
| WO2012068317A2 (en) * | 2010-11-16 | 2012-05-24 | Excelimmune, Inc. | Methods for producing recombinant proteins |
| JP7235436B2 (ja) * | 2014-11-10 | 2023-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 細胞の表面上にポリペプチドを発現させるための組成物および方法 |
| AU2020322221A1 (en) * | 2019-07-26 | 2022-03-24 | Janssen Biotech, Inc. | Anti-hK2 chimeric antigen receptor (CAR) |
-
2022
- 2022-06-08 KR KR1020247000497A patent/KR20240021211A/ko active Pending
- 2022-06-08 CA CA3222756A patent/CA3222756A1/en active Pending
- 2022-06-08 AU AU2022291273A patent/AU2022291273A1/en active Pending
- 2022-06-08 WO PCT/IB2022/055355 patent/WO2022259190A1/en not_active Ceased
- 2022-06-08 JP JP2023575724A patent/JP2024520790A/ja active Pending
- 2022-06-08 MX MX2023014793A patent/MX2023014793A/es unknown
- 2022-06-08 BR BR112023025616A patent/BR112023025616A2/pt not_active Application Discontinuation
- 2022-06-08 EP EP22735984.1A patent/EP4352217A1/en active Pending
- 2022-06-08 IL IL309179A patent/IL309179A/en unknown
- 2022-06-08 CN CN202280041004.7A patent/CN117480253A/zh active Pending
- 2022-06-08 US US17/835,671 patent/US20220403397A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4352217A1 (en) | 2024-04-17 |
| CN117480253A (zh) | 2024-01-30 |
| US20220403397A1 (en) | 2022-12-22 |
| AU2022291273A1 (en) | 2024-01-25 |
| KR20240021211A (ko) | 2024-02-16 |
| BR112023025616A2 (pt) | 2024-02-27 |
| WO2022259190A1 (en) | 2022-12-15 |
| CA3222756A1 (en) | 2022-12-15 |
| JP2024520790A (ja) | 2024-05-24 |
| IL309179A (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9813608A (pt) | Polipeptìdeo isolado, sequências de ácido nucleico isolado e mutante, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, processos para produzir uma sequência de ácido nucleico mutante, para produzir um polipeptìdeo, para produzir um mutante de uma célula originária e para produzir uma proteìna, e, célula mutante | |
| AU2590901A (en) | Il-17 homologous polypeptides and therapeutic uses thereof | |
| ATE258060T1 (de) | Tadg15: eine extrazelluläre serinprotease überexprimiert in brust- und eierstock-karzinomen | |
| WO2005017149A8 (en) | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site | |
| CA2087261A1 (en) | Purification directed cloning of peptides | |
| EA200100419A1 (ru) | Трансформационная система в области грибов гифомицетов-хозяев | |
| WO1998056927A3 (en) | Nucleic acids encoding polypeptide having protease activity | |
| ES8500325A1 (es) | Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana. | |
| ES8802394A1 (es) | Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana. | |
| BR0009393A (pt) | Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente | |
| WO1995006735A3 (en) | Nucleotide sequences for novel protein tyrosine phosphatases | |
| DE60137829D1 (de) | Menschliche stra6 polypeptide | |
| MX2025009545A (es) | Metodos y composiciones para la administracion de sistemas de vector dual otoferlin | |
| DE69535696D1 (de) | Tripeptidyl-aminopeptidase | |
| MX2023002413A (es) | Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados. | |
| MX2023014793A (es) | Codificacion de acido nucleico para la proteína de fusión klk2-gpi, células recombinantes y usos de estos. | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| WO2022081728A3 (en) | Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same | |
| EP0238473A3 (en) | Serine protease inhibitors | |
| DE69635081D1 (de) | Enamel-matrix bezogene polypeptide | |
| DE69834046D1 (de) | Extrazelluläre serinprotease | |
| Horstmann et al. | Host tissue destruction by Entamoeba histolytica: molecules mediating adhesion, cytolysis, and proteolysis | |
| DK1546302T3 (da) | Fremgangsmåder til fremstilling af pattedyrs-trypsiner | |
| WO2004056316A8 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
| Scholze | 23. Amoebapain, the major proteinase of pathogenic Entamoeba histolytica |